Insider Selling: Disc Medicine (NASDAQ:IRON) CEO Sells 33,000 Shares of Stock

Key Points

• Disc Medicine CEO John Quisel sold 33,000 shares at an average price of $79.15, generating approximately $2.61 million. His direct ownership fell 12.74% to 226,064 shares.
• IRON shares rose 0.2% to $80.20, while the company reported a quarterly loss of $1.54 per share—better than analysts’ expected loss of $1.71.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $106.50; institutional investors own 83.7% of the stock.

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CEO John Quisel sold 33,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $79.15, for a total value of $2,611,950.00. Following the completion of the transaction, the chief executive officer directly owned 226,064 shares in the company, valued at $17,892,965.60. This trade represents a 12.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Disc Medicine Trading Up 0.2%

IRON stock traded up $0.15 during trading on Tuesday, reaching $80.20. 336,995 shares of the stock traded hands, compared to its average volume of 574,631. The firm has a market capitalization of $307.17 million, a PE ratio of -12.19 and a beta of 1.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. The business's 50 day moving average price is $74.89 and its 200-day moving average price is $69.89. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, topping analysts' consensus estimates of ($1.71) by $0.17. As a group, sell-side analysts forecast that Disc Medicine, Inc. will post -6.61 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on IRON shares. Wedbush reiterated an "outperform" rating and set a $88.00 price objective on shares of Disc Medicine in a research note on Wednesday, June 10th. Morgan Stanley reissued an "overweight" rating and issued a $90.00 target price on shares of Disc Medicine in a research note on Monday. HC Wainwright lifted their target price on shares of Disc Medicine from $118.00 to $120.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Disc Medicine in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded Disc Medicine from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Disc Medicine has an average rating of "Moderate Buy" and an average target price of $106.50.

Hedge Funds Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently bought and sold shares of IRON. State of Wyoming acquired a new stake in Disc Medicine in the second quarter valued at approximately $25,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Disc Medicine during the fourth quarter worth $33,000. Allworth Financial LP purchased a new position in shares of Disc Medicine in the second quarter valued at $46,000. KBC Group NV purchased a new position in shares of Disc Medicine in the fourth quarter valued at $80,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Disc Medicine during the 4th quarter valued at $141,000. Hedge funds and other institutional investors own 83.70% of the company's stock.

About Disc Medicine

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source